Direct cardiac reprogramming: A new technology for cardiac repair

J Mol Cell Cardiol. 2023 May:178:51-58. doi: 10.1016/j.yjmcc.2023.03.008. Epub 2023 Mar 23.

Abstract

Cardiovascular disease is one of the leading causes of morbidity and mortality worldwide, with myocardial infarctions being amongst the deadliest manifestations. Reduced blood flow to the heart can result in the death of cardiac tissue, leaving affected patients susceptible to further complications and recurrent disease. Further, contemporary management typically involves a pharmacopeia to manage the metabolic conditions contributing to atherosclerotic and hypertensive heart disease, rather than regeneration of the damaged myocardium. With modern healthcare extending lifespan, a larger demographic will be at risk for heart disease, driving the need for novel therapeutics that surpass those currently available in efficacy. Transdifferentiation and cellular reprogramming have been looked to as potential methods for the treatment of diseases throughout the body. Specifically targeting the fibrotic cells in cardiac scar tissue as a source to be reprogrammed into induced cardiomyocytes remains an appealing option. This review aims to highlight the history of and advances in cardiac reprogramming and describe its translational potential as a treatment for cardiovascular disease.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Cellular Reprogramming / genetics
  • Heart Diseases* / metabolism
  • Humans
  • Myocardial Infarction* / metabolism
  • Myocardium / metabolism
  • Myocytes, Cardiac / metabolism
  • Technology